Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Entelos has reported that Pfizer has signed an agreement to expand and continue research using its cardiovascular PhysioLab platform. The expanded research will focus on identifying biomarkers and interpretation of clinical study data.
Subscribe to our email newsletter
The Entelos cardiovascular PhysioLab platform is a predictive computer model that simulates patients and drug effects, and represents key biological mechanisms and disease processes that can help to explain the underlying causes of heart attacks, strokes, and other serious cardiovascular conditions in multiple patient types.
The platform mathematically represents the relative contribution of circulating lipids, systemic inflammation and local vessel inflammation to the progression of atherosclerosis, a key driver leading to heart disease. Entelos has supported a variety of preclinical and clinical research in prior work conducted with Pfizer over multiple stages.
James Karis, president and CEO of Entelos, said: “We believe that our cardiovascular disease platform can help Pfizer gain even greater value from the tremendous amount of information available in their historical clinical trial databases. We look forward to continuing our work with Pfizer and to conducting research on their highest priority projects in cardiovascular disease, cholesterol regulation, and atherosclerosis.”